Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged
Executive Summary
Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.
You may also be interested in...
Samsung Bioepis’s Biosimilar Enbrel ‘Substitutable’ In Australia As Pfizer Patent Case Is Rebuffed
Samsung Bioepis’s Brenzys has become the second biosimilar product to be reimbursed as substitutable at the pharmacy level in Australia, and a court has scotched Pfizer’s plans to initiate a patent infringement claim over the manufacturing process for the Enbrel/etanercept biosimilar.
Samsung Bioepis’s Biosimilar Enbrel ‘Substitutable’ In Australia As Pfizer Patent Case Is Rebuffed
Samsung Bioepis’s Brenzys has become the second biosimilar product to be reimbursed as substitutable at the pharmacy level in Australia, and a court has scotched Pfizer’s plans to initiate a patent infringement claim over the manufacturing process for the Enbrel/etanercept biosimilar.
Brazil: The Next Hot Spot For Biosimilar Substitution?
Biosimilars manufacturers could reach a wider patient population in Brazil if they can demonstrate interchangeably, as they do not face the potential barrier of discretion from states.